Article
Anti-CD19 CAR T as a feasible and safe therapy for refractory/relapsed mixed phenotype acute leukemia (MPAL) patients
2022-01-20
Abstract excerpt
Mixed phenotype acute leukemia (MPAL) is a relatively rare and heterogeneous group of diseases, which account for 2-5% of leukemia. So far, no optimal treatment regimens have been established for MPAL patients. CD19 chimeric antigen receptor T (CAR T) therapy have shown remarkable efficacy in B-ALL patients. In this study, 5 MPAL patients received CD19 CAR T cell infusion and 3 out of 5 patients (60%) achieved com...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f2582eea-d67c-586a-85a4-8fcb2a6cbe6b
- DOI
- 10.22541/au.164264604.42706238/v1
